Life Sciences

  • May 07, 2026

    Judge, In 'Difficult Position,' OKs Rare Patent Defense

    A Massachusetts federal judge found himself in what he said was a "difficult position" in allowing an unusual defense to be advanced in a patent infringement case related to blood pumps in light of criticism of the defense from the Federal Circuit.

  • May 07, 2026

    $495M Win Upheld In Abbott Baby Formula Bellwether Trial

    A Missouri appellate panel on Tuesday upheld a trial win of $95 million in compensatory damages and $400 million in punitive damages over bellwether claims that Abbott Laboratories' baby formula caused a premature baby to suffer a fully disabling condition.

  • May 07, 2026

    Bayer Sued Over Healthy Sperm Claim On 'One A Day' Pill

    Bayer AG has been hit with a proposed class action in New York federal court alleging that claims on its Men's One A Day Pre-Conception Health Multivitamin supplements misleadingly convey that they could improve chances of conception and support sperm health.

  • May 07, 2026

    Bayer Loses Bid To Undo Class In 'One A Day' Label Suit

    A New York federal judge on Wednesday declined to decertify a class action alleging that Bayer's "One A Day" gummy vitamins deceive consumers about serving sizes, allowing the case to continue since there's evidence that a significant number of consumers could be confused.

  • May 07, 2026

    Liberty Left Client Info Vulnerable To Hackers, Suit Alleges

    Liberty Mutual Insurance Co. faces a proposed consumer class action alleging it failed to effectively safeguard private information for current and former clients after hackers claimed they stole information and sought a ransom payment.

  • May 07, 2026

    Judge Knocks Out Pfizer Partner's Vax Case Against GSK

    A Delaware federal judge on Thursday threw out a suit seeking a finding that a drug developer that partnered with Pfizer and BioNTech on their COVID-19 vaccine didn't infringe drugmaker GlaxoSmithKline's patents.

  • May 07, 2026

    Pharma Cos. Hit With $2M Judgment Over CBD Investor Fraud

    A California federal judge has issued final judgments against a pharmaceutical company, its CEO and an affiliate on claims from the U.S. Securities and Exchange Commission that they defrauded investors of $6.6 million, hitting them with more than $2 million in damages and civil penalties.

  • May 07, 2026

    AstraZeneca Reps Fight To Keep Opt-Ins In Pay Bias Suit

    Female pharmaceutical sales representatives in an AstraZeneca equal pay suit have urged an Illinois federal court to reject the company's bid to dismiss two dozen opt-in plaintiffs for refusing discovery, saying the women feared retaliation and career consequences.

  • May 07, 2026

    Ex‑Novartis Atty Wins Revival Of Whistleblower Claims

    The New Jersey state appeals court on Thursday revived five whistleblower claims brought by a former Novartis compliance attorney, finding that a trial judge wrongly treated a years‑long pattern of alleged retaliation as discrete, time‑barred events rather than a continuous campaign culminating in her 2021 termination.

  • May 07, 2026

    Davis Polk-Led Roche To Pay Up To $1.05B For PathAI

    Davis Polk & Wardwell LLP is advising Roche on a deal announced Thursday that would see the Swiss healthcare company purchase a Boston-based, AI-powered digital pathology company for up to $1.05 billion.

  • May 07, 2026

    King & Spalding Adds Congressional Health Policy Duo In DC

    Two former congressional staffers experienced in health policy recently joined King & Spalding LLP in its Washington, D.C., office, the firm announced this week.

  • May 07, 2026

    Gilead Accuses Pharmacies Of Selling Counterfeit HIV Drugs

    Gilead Sciences has sued several New York City pharmacies claiming they sold counterfeit HIV medication bearing the Gilead brand.

  • May 07, 2026

    Toss Of Ex-Shkreli Atty's Deal May Be Error, 2nd Circ. Hints

    A Second Circuit judge hinted Thursday that a trial judge may have erred in rejecting a retirement-fund garnishment deal that would have protected Martin Shkreli's convicted former lawyer from a potential $1 million "punitive tax event."

  • May 07, 2026

    FBI Assistant GC Joins FBI Alum At Fenwick

    Fenwick & West LLP has hired the former assistant general counsel of the FBI, who will work as a counsel to support technology and life sciences companies and who is rejoining the former FBI director's chief of staff in the Washington, D.C., office.

  • May 06, 2026

    Corcept Must Face Most Teva Mifepristone Antitrust Claims

    A California federal judge on Tuesday once again mostly refused to throw out Teva Pharmaceuticals' claims that Corcept Therapeutics used patent system abuse, bribes and exclusive dealing to block generic competition to its cortisol disorder treatment, finding that at this stage in the litigation the allegations are adequate.

  • May 06, 2026

    J&J, Tolmar Settle Patent Case Over Antipsychotic Drug

    A federal court Wednesday signed off on a consent judgment in a patent case brought by a Johnson & Johnson unit that prevents Tolmar Inc. from selling a generic version of the blockbuster schizophrenia drug Invega Sustenna.

  • May 06, 2026

    'Do Not Use This Report': J&J Hid Asbestos Test, Jury Told

    Johnson & Johnson and a consultant it hired in the 1970s altered the conclusions of tests that found alarming levels of asbestos in the company's talc products before giving different results to the U.S. Food and Drug Administration, a former FDA commissioner told a Los Angeles jury Wednesday.

  • May 06, 2026

    Trulieve Twists Patent Pleading Standard, Cannabis Co. Says

    A cannabis patent holder urged a Florida federal court to reject Trulieve Inc.'s effort to toss an infringement complaint, arguing that proof of its claims isn't needed when initially filing a lawsuit. 

  • May 06, 2026

    Judge Questions OMB Justification For Voiding Grants

    A Massachusetts federal judge on Wednesday pushed back on arguments by the Trump administration that federal agency grants are subject to termination at any time based solely on a change in priorities — a situation, she suggested, that would essentially render any contracts with the government "illusory."

  • May 06, 2026

    Judge Won't Certify Minn. Fraud Question In Cancer Drug MDL

    A New Jersey federal judge won't ask the Supreme Court of Minnesota to weigh in on whether an insurer can pursue claims using a state law typically reserved for the attorney general in litigation alleging drugmaker Celgene used charitable donations to manipulate the price of cancer drugs.

  • May 06, 2026

    Calif. Justices Seem Divided On Gilead HIV Negligence Claim

    The California Supreme Court appeared split Wednesday over whether Gilead should face a negligence claim for allegedly withholding a safer HIV drug from the market to maximize profits from an older drug with more harmful side effects. 

  • May 06, 2026

    9th Circ. Won't Revive Hospital Workers' Vaccine Bias Suit

    The Ninth Circuit refused Wednesday to reopen a religious bias lawsuit accusing a Washington hospital of unlawfully denying employees' requests to avoid a COVID-19 vaccination mandate, finding that the medical center demonstrated that exemptions would've been too burdensome under a 2023 U.S. Supreme Court decision.

  • May 06, 2026

    Alto Says Investors Use Hindsight In Suit Over Drug Trial

    Alto Neuroscience has urged a California federal judge to toss an investor suit alleging the psychiatric biotech company and its top brass overstated the efficacy of their lead drug candidate for treating major depressive disorder, saying the suit is a "classic case of trying to plead fraud by hindsight."

  • May 06, 2026

    CellCentric Closes Latest Funding Round With $220M In Tow

    Clinical-stage biotechnology company CellCentric on Wednesday revealed that it closed its oversubscribed Series D financing round after securing $220 million from investors.

  • May 05, 2026

    DC Circ. Judge Jabs Pharma Atty For 10 Minutes In Price Fight

    The first D.C. Circuit showdown in widespread drug pricing litigation Tuesday appeared unlikely to deliver a badly needed win to the pharmaceutical industry, as a top manufacturer's attorney faced a cool reception generally and an extended barrage of skepticism from one judge.

Expert Analysis

  • Why Product-Based Public Nuisance Claims May Be Waning

    Author Photo

    The Maryland Supreme Court's recent decision in Express Scripts v. Anne Arundel County is the latest in a national trend of rulings rejecting product-based public nuisance claims — but other forms of government litigation against companies that allegedly increase the cost of public services are likely to continue, say attorneys at Simpson Thacher.

  • Improving Well-Being In Law, 10 Years After Landmark Study

    Author Photo

    An important 2016 study revealed significant substance abuse and mental health issues among lawyers, and while the findings helped normalize the conversation around these topics, a decade later, structural change is still needed, says Denise Robinson at PLI.

  • How To Gear Up For Trump's Pharma Tariffs

    Author Photo

    President Donald Trump's proclamation establishing tariffs on certain pharmaceutical products holds a few areas of ambiguity that companies should review and prepare for before the tariffs come into effect later this year, say attorneys at Arnold & Porter.

  • How The Coming Months Will Shape State Drug Price Boards

    Author Photo

    The future of state prescription drug affordability boards may be determined in the next few months, between an upcoming court decision in a challenge against state authority to set drug prices, and pending state decisions about whether to use federal Medicare maximum fair prices as reference, say Michael Kolber, Steven Chen and Kelechi Ezealaji at Manatt.

  • High Court 'Skinny Label' Case Will Matter To Tech Litigators

    Author Photo

    Hikma v. Amarin, set for oral argument in the U.S. Supreme Court on Wednesday, has potential to affect not just generic drug label-based evidence in patent cases, but also how technology inducement cases are presented and proven, says attorney Abdul Abdullahi.

  • How Food, Beverage Claims May Preview Cosmetic Litigation

    Author Photo

    Class action litigation targeting cosmetics and personal care products is accelerating, with a playbook that comes from the food and beverage industry — and the defenses that succeeded, and failed, in past class actions offer a critical road map for beauty and personal care brands, say attorneys at Crowell.

  • Court's HRSA Policy Reversal Leaves 340B Rules Murky

    Author Photo

    A D.C. federal court's recent decision in Premier v. U.S. Department of Health limits the Health Resources and Services Administration's ability to enforce long-standing Section 340B interpretations through subregulatory guidance, leaving open core statutory questions about purchasing models, inventory classification and program oversight, says Martha Cramer at Hooper Lundy.

  • Series

    Officiating Football Makes Me A Better Lawyer

    Author Photo

    Though they may seem to have little in common, officiating football has sharpened many of the same skills that define effective lawyering in management-side labor and employment: preparation, judgment, composure, credibility and ability to make difficult decisions in real time, says Josh Nadreau at Fisher Phillips.

  • Fresenius Ruling May Shift Anti-Kickback Enforcement

    Author Photo

    The Ninth Circuit's recent decision in Fresenius v. Bonta suggests that businesses have a First Amendment right to donate to certain charities, even if those donations are motivated by economic self-interest, potentially calling into question years of Anti-Kickback Statute proceedings against pharmaceutical manufacturers for making similar donations, says Jonah Knobler at Patterson Belknap.

  • Written Consent Ruling May Signal Change For Telemarketing

    Author Photo

    The Fifth Circuit's ruling in Bradford v. Sovereign Pest Control is a takedown of the Federal Communications Commission's prior express written consent regulation, and because Loper Bright empowers courts to disregard agency interpretations, Telephone Consumer Protection Act litigants now have an opportunity to challenge previously settled FCC regulations, orders and interpretations, say attorneys at Manatt.

  • Series

    Law School's Missed Lessons: How To Draft Pleadings

    Author Photo

    Most law school graduates step into their first jobs without ever having drafted a complaint, answer, motion or other type of pleading, but that gap can be closed by understanding the strategy embedded in every filing, writing with clarity and purpose, and seeking feedback at every step, says Eric Yakaitis at Haug Barron.

  • At The Fed. Circ., Means-Plus-Function Is Not Quite Dead

    Author Photo

    Recent Federal Circuit opinions confirm that means-plus-function claims continue to be drafted, issued, litigated and even infringed — but minding the restrictions imposed over the years by courts and statute requires three steps, says Jay Yates at Patterson & Sheridan.

  • E-Discovery Quarterly: Recent Rulings On ESI Control

    Author Photo

    Several recent federal court decisions have perpetuated a split over what constitutes “control” of electronically stored information — with judges divided on whether the standard should turn on a party's legal right or practical ability to obtain the information, say attorneys at Sidley.

  • Opinion

    USPTO Should Let Inventors Valuate Patents In Prosecution

    Author Photo

    By building patent valuation into the application process, rather than waiting until potential litigation years down the line, the U.S. Patent and Trademark Office would streamline the process for inventors protecting and enforcing their patents, says John Powers at Powers IP.

  • 2 Discovery Rulings Break With Heppner On AI Privilege Issue

    Author Photo

    While a New York federal court’s recent ruling in U.S. v. Heppner suggests that some litigants’ communications with AI tools are discoverable, two other recent federal court decisions demonstrate that such interactions generally qualify for work-product protection under the Federal Rules of Civil Procedure, says Joshua Dunn at Brown Rudnick.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.